Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High – Should You Buy?

Posted by Francis Steltz on Jun 29th, 2026

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $126.59 and last traded at $120.5520, with a volume of 23263 shares trading hands. The stock had previously closed at $121.88.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. The Goldman Sachs Group reiterated a “neutral” rating and set a $110.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Citizens Jmp boosted their price target on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a report on Wednesday, May 6th. Wall Street Zen cut Protagonist Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Johnson Rice reiterated a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. Finally, JPMorgan Chase & Co. lifted their target price on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $115.21.

Get Our Latest Stock Analysis on Protagonist Therapeutics

Protagonist Therapeutics Price Performance

The firm has a market cap of $7.67 billion, a P/E ratio of -66.21 and a beta of 1.86. The business’s 50-day moving average is $104.39 and its two-hundred day moving average is $95.21.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The firm had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

Insider Buying and Selling

In related news, Director Bryan Giraudo sold 36,000 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $100.14, for a total transaction of $3,605,040.00. Following the completion of the transaction, the director directly owned 27,825 shares of the company’s stock, valued at approximately $2,786,395.50. This represents a 56.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William D. Waddill sold 9,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total value of $1,061,460.00. Following the transaction, the director directly owned 7,825 shares of the company’s stock, valued at $922,880.50. This trade represents a 53.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 162,880 shares of company stock worth $16,539,792 over the last 90 days. 5.19% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. NEXTBio Capital Management LP bought a new stake in Protagonist Therapeutics during the fourth quarter worth $20,055,000. Jennison Associates LLC bought a new position in shares of Protagonist Therapeutics in the 4th quarter valued at about $28,924,000. Farallon Capital Management LLC increased its stake in shares of Protagonist Therapeutics by 0.4% during the 3rd quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock worth $411,601,000 after purchasing an additional 24,000 shares during the last quarter. Eagle Health Investments LP acquired a new position in shares of Protagonist Therapeutics during the 4th quarter worth about $5,005,000. Finally, Mangrove Partners IM LLC raised its holdings in shares of Protagonist Therapeutics by 21.0% in the 3rd quarter. Mangrove Partners IM LLC now owns 478,413 shares of the company’s stock valued at $31,781,000 after purchasing an additional 83,030 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

(Get Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.